PF-Atlas › Clinical Trials › NCT05166694

Navitoclax + Nintedanib in IPF

Navitoclax · Senolytics · Phase 2

Registry ID
NCT05166694
Phase
Phase 2
Status
Recruiting
Drug / intervention
Navitoclax (ABT-263)
Mechanism
Senolytics
Sponsor
Multiple
Start
2022-06

About this trial

Navitoclax is evaluated in NCT05166694, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Multiple, targeting senolytics. Current status: Recruiting.

View NCT05166694 on ClinicalTrials.gov →

Explore related

Navitoclax — Treatment profileAll Navitoclax trialsSenolytics mechanismAll IPF trials

Related trials

Dasatinib + Quercetin — NCT04262635Fisetin — NCT04537533
Medical disclaimer. This page summarizes public trial data for NCT05166694 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.